Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.
2.

A drug response predictor to guide treatment for breast cancer.

Buhl IK, Jensen PB, Kappel Buhl AS, Knudsen S.

Pharmacogenomics. 2019 Apr;20(5):307-309. doi: 10.2217/pgs-2018-0195. Epub 2019 Apr 15. No abstract available.

3.

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.

Buhl ASK, Christensen TD, Christensen IJ, Nelausen KM, Balslev E, Knoop AS, Brix EH, Svensson E, Glavicic V, Luczak A, Langkjer ST, Linnet S, Jakobsen EH, Bogovic J, Ejlertsen B, Rasmussen A, Hansen A, Knudsen S, Nielsen D, Jensen PB.

Breast Cancer Res Treat. 2018 Nov;172(2):391-400. doi: 10.1007/s10549-018-4918-4. Epub 2018 Aug 11.

4.

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.

Buhl IK, Santoni-Rugiu E, Ravn J, Hansen A, Christensen IJ, Jensen T, Pratt B, Askaa J, Jensen PB, Knudsen S, Sørensen JB.

PLoS One. 2018 Mar 22;13(3):e0194609. doi: 10.1371/journal.pone.0194609. eCollection 2018.

5.

Single-centre experience with the Impella CP, 5.0 and RP in 109 consecutive patients with profound cardiogenic shock.

Jensen PB, Kann SH, Veien KT, Møller-Helgestad OK, Dahl JS, Rud CS, Jensen MK, Jensen LO, Schmidt H, Møller JE.

Eur Heart J Acute Cardiovasc Care. 2018 Feb;7(1):53-61. doi: 10.1177/2048872617743194. Epub 2017 Nov 17.

PMID:
29148290
6.

Drug response prediction in high-risk multiple myeloma.

Vangsted AJ, Helm-Petersen S, Cowland JB, Jensen PB, Gimsing P, Barlogie B, Knudsen S.

Gene. 2018 Feb 20;644:80-86. doi: 10.1016/j.gene.2017.10.071. Epub 2017 Nov 6.

PMID:
29122646
7.

Social inequality in diabetes patients' morbidity patterns from diagnosis to death - A Danish register-based investigation.

Sortsø C, Lauridsen J, Emneus M, Green A, Jensen PB.

Scand J Public Health. 2018 Feb;46(1):92-101. doi: 10.1177/1403494817713648. Epub 2017 Jul 1.

PMID:
28671031
8.

Socioeconomic inequality of diabetes patients' health care utilization in Denmark.

Sortsø C, Lauridsen J, Emneus M, Green A, Jensen PB.

Health Econ Rev. 2017 Dec;7(1):21. doi: 10.1186/s13561-017-0155-5. Epub 2017 May 26.

9.

Combining light-harvesting with detachability in high-efficiency thin-film silicon solar cells.

Ram SK, Desta D, Rizzoli R, Bellettato M, Lyckegaard F, Jensen PB, Jeppesen BR, Chevallier J, Summonte C, Larsen AN, Balling P.

Nanoscale. 2017 Jun 1;9(21):7169-7178. doi: 10.1039/c7nr00658f.

PMID:
28513716
10.

Cancer of unknown primary: Registered procedures compared with national integrated cancer pathway for illuminating external validity.

Dyrvig AK, Yderstræde KB, Gerke O, Jensen PB, Hess S, Høilund-Carlsen PF, Green A.

Medicine (Baltimore). 2017 Apr;96(16):e6693. doi: 10.1097/MD.0000000000006693.

11.

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.

Prahm KP, Høgdall C, Karlsen MA, Christensen IJ, Novotny GW, Knudsen S, Hansen A, Jensen PB, Jensen T, Mirza MR, Ekmann-Gade AW, Nedergaard L, Høgdall E.

PLoS One. 2017 Mar 23;12(3):e0174300. doi: 10.1371/journal.pone.0174300. eCollection 2017.

12.

Novel back-reflector architecture with nanoparticle based buried light-scattering microstructures for improved solar cell performance.

Desta D, Ram SK, Rizzoli R, Bellettato M, Summonte C, Jeppesen BR, Jensen PB, Tsao YC, Wiggers H, Pereira RN, Balling P, Larsen AN.

Nanoscale. 2016 Jun 9;8(23):12035-46. doi: 10.1039/c6nr00259e.

PMID:
27244247
13.

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.

Buhl IK, Gerster S, Delorenzi M, Jensen T, Jensen PB, Bosman F, Tejpar S, Roth A, Brunner N, Hansen A, Knudsen S.

PLoS One. 2016 May 12;11(5):e0155123. doi: 10.1371/journal.pone.0155123. eCollection 2016.

14.

Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer.

Winther M, Knudsen S, Dahlgaard J, Jensen T, Hansen A, Jensen PB, Tramm T, Alsner J, Nordsmark M.

PLoS One. 2016 Feb 17;11(2):e0148070. doi: 10.1371/journal.pone.0148070. eCollection 2016.

15.

Incidence, morbidity, mortality, and prevalence of diabetes in Denmark, 2000-2011: results from the Diabetes Impact Study 2013.

Green A, Sortsø C, Jensen PB, Emneus M.

Clin Epidemiol. 2015 Oct 23;7:421-30. doi: 10.2147/CLEP.S88577. eCollection 2015. Erratum in: Clin Epidemiol. 2016;8:7.

16.

Societal costs of diabetes mellitus in Denmark.

Sortsø C, Green A, Jensen PB, Emneus M.

Diabet Med. 2016 Jul;33(7):877-85. doi: 10.1111/dme.12965. Epub 2015 Oct 29.

17.

Biotin starvation causes mitochondrial protein hyperacetylation and partial rescue by the SIRT3-like deacetylase Hst4p.

Madsen CT, Sylvestersen KB, Young C, Larsen SC, Poulsen JW, Andersen MA, Palmqvist EA, Hey-Mogensen M, Jensen PB, Treebak JT, Lisby M, Nielsen ML.

Nat Commun. 2015 Jul 9;6:7726. doi: 10.1038/ncomms8726.

18.

Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines.

Warrer P, Jensen PB, Aagaard L, Jensen LJ, Brunak S, Krag MH, Rossing P, Almdal T, Andersen HU, Hansen EH.

J Res Pharm Pract. 2015 Apr-Jun;4(2):64-72. doi: 10.4103/2279-042X.155753.

19.
20.

Validation of the danish national diabetes register.

Green A, Sortsø C, Jensen PB, Emneus M.

Clin Epidemiol. 2014 Dec 18;7:5-15. doi: 10.2147/CLEP.S72768. eCollection 2015.

21.

Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis.

Hall A, Parhamifar L, Lange MK, Meyle KD, Sanderhoff M, Andersen H, Roursgaard M, Larsen AK, Jensen PB, Christensen C, Bartek J, Moghimi SM.

Biochim Biophys Acta. 2015 Mar;1847(3):328-342. doi: 10.1016/j.bbabio.2014.12.002. Epub 2014 Dec 5.

22.

Designing mixed metal halide ammines for ammonia storage using density functional theory and genetic algorithms.

Jensen PB, Lysgaard S, Quaade UJ, Vegge T.

Phys Chem Chem Phys. 2014 Sep 28;16(36):19732-40. doi: 10.1039/c4cp03133d.

PMID:
25115581
23.

Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients.

Jensen AB, Moseley PL, Oprea TI, Ellesøe SG, Eriksson R, Schmock H, Jensen PB, Jensen LJ, Brunak S.

Nat Commun. 2014 Jun 24;5:4022. doi: 10.1038/ncomms5022.

24.

Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.

Munk Jensen M, Erichsen KD, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

PLoS One. 2013 Dec 26;8(12):e85126. doi: 10.1371/journal.pone.0085126. eCollection 2013.

25.

Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.

Christensen MK, Erichsen KD, Olesen UH, Tjørnelund J, Fristrup P, Thougaard A, Nielsen SJ, Sehested M, Jensen PB, Loza E, Kalvinsh I, Garten A, Kiess W, Björkling F.

J Med Chem. 2013 Nov 27;56(22):9071-88. doi: 10.1021/jm4009949. Epub 2013 Nov 13.

PMID:
24164086
26.

Dictionary construction and identification of possible adverse drug events in Danish clinical narrative text.

Eriksson R, Jensen PB, Frankild S, Jensen LJ, Brunak S.

J Am Med Inform Assoc. 2013 Sep-Oct;20(5):947-53. doi: 10.1136/amiajnl-2013-001708. Epub 2013 May 23.

27.

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.

Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P, Christensen C.

Oncotarget. 2013 Apr;4(4):584-99.

28.

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

BMC Cancer. 2013 Apr 1;13:168. doi: 10.1186/1471-2407-13-168.

29.

Transcatheter aortic valve implantation in a patient with circulatory collapse, using the LUCAS® chest compression system.

Jensen PB, Andersen C, Nissen H.

Catheter Cardiovasc Interv. 2013 May;81(6):1084-6. doi: 10.1002/ccd.24590. Epub 2013 Feb 21.

PMID:
23436538
30.

[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Bzorek M, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2013;8(1):e53410. doi: 10.1371/journal.pone.0053410. Epub 2013 Jan 4.

31.

Reply to 'Mining electronic health records: an additional perspective'.

Jensen PB, Jensen LJ, Brunak S.

Nat Rev Genet. 2013 Jan;14(1):75. doi: 10.1038/nrg3208-c2. No abstract available.

PMID:
23247438
32.

[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.

Munk Jensen M, Erichsen KD, Björkling F, Madsen J, Jensen PB, Sehested M, Højgaard L, Kjær A.

PLoS One. 2012;7(11):e50618. doi: 10.1371/journal.pone.0050618. Epub 2012 Nov 30.

33.

Mining electronic health records: towards better research applications and clinical care.

Jensen PB, Jensen LJ, Brunak S.

Nat Rev Genet. 2012 May 2;13(6):395-405. doi: 10.1038/nrg3208. Review.

PMID:
22549152
34.

Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells.

Invernizzi F, D'Amato I, Jensen PB, Ravaglia S, Zeviani M, Tiranti V.

Mitochondrion. 2012 Mar;12(2):328-35. doi: 10.1016/j.mito.2012.01.001. Epub 2012 Jan 28.

35.

Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.

Langer SW, Thougaard AV, Sehested M, Jensen PB.

Cancer Chemother Pharmacol. 2012 Feb;69(2):573-6. doi: 10.1007/s00280-011-1794-6. Epub 2011 Dec 6.

PMID:
22143379
36.

Using electronic patient records to discover disease correlations and stratify patient cohorts.

Roque FS, Jensen PB, Schmock H, Dalgaard M, Andreatta M, Hansen T, Søeby K, Bredkjær S, Juul A, Werge T, Jensen LJ, Brunak S.

PLoS Comput Biol. 2011 Aug;7(8):e1002141. doi: 10.1371/journal.pcbi.1002141. Epub 2011 Aug 25.

37.

Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia.

Jensen PB, Larsen PJ, Karlsen C, Jensen HI, Holst JJ, Madsen OD.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:60-8. doi: 10.1111/j.1463-1326.2011.01439.x. Review.

PMID:
21824258
38.

Bioenergetic profile experiment using C2C12 myoblast cells.

Nicholls DG, Darley-Usmar VM, Wu M, Jensen PB, Rogers GW, Ferrick DA.

J Vis Exp. 2010 Dec 6;(46). pii: 2511. doi: 10.3791/2511.

39.

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S, Christensen MK, Fristrup P, Thougaard AV, Björkling F, Jensen PB, Nielsen SJ, Sehested M.

BMC Cancer. 2010 Dec 12;10:677. doi: 10.1186/1471-2407-10-677.

40.

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Björkling F, Madsen J, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2010 Sep 24;5(9):e12965. doi: 10.1371/journal.pone.0012965.

41.

Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential.

Trojel-Hansen C, Erichsen KD, Christensen MK, Jensen PB, Sehested M, Nielsen SJ.

Cancer Chemother Pharmacol. 2011 Jul;68(1):127-38. doi: 10.1007/s00280-010-1453-3. Epub 2010 Sep 18.

PMID:
20852860
42.

Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.

Christensen MK, Erichsen KD, Trojel-Hansen C, Tjørnelund J, Nielsen SJ, Frydenvang K, Johansen TN, Nielsen B, Sehested M, Jensen PB, Ikaunieks M, Zaichenko A, Loza E, Kalvinsh I, Björkling F.

J Med Chem. 2010 Oct 14;53(19):7140-5. doi: 10.1021/jm100763j.

PMID:
20845961
43.

Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study.

Verbeke F, Van Biesen W, Honkanen E, Wikström B, Jensen PB, Krzesinski JM, Rasmussen M, Vanholder R, Rensma PL; CORD Study Investigators.

Clin J Am Soc Nephrol. 2011 Jan;6(1):153-9. doi: 10.2215/CJN.05120610. Epub 2010 Sep 9.

44.

Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.

Beck HC, Petersen J, Nielsen SJ, Morsczeck C, Jensen PB, Sehested M, Grauslund M.

Electrophoresis. 2010 Aug;31(16):2714-21. doi: 10.1002/elps.201000033. Erratum in: Electrophoresis. 2010 Oct;31(21):3619. Morszeck, Christian [corrected to Morsczeck, Christian].

PMID:
20717991
45.

A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.

Olesen UH, Thougaard AV, Jensen PB, Sehested M.

Mol Cancer Ther. 2010 Jun;9(6):1609-17. doi: 10.1158/1535-7163.MCT-09-1130. Epub 2010 Jun 1.

46.

A Wnt oscillator model for somitogenesis.

Jensen PB, Pedersen L, Krishna S, Jensen MH.

Biophys J. 2010 Mar 17;98(6):943-50. doi: 10.1016/j.bpj.2009.11.039.

47.

A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.

Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, Sehested M.

Toxicology. 2010 Feb 28;269(1):67-72. doi: 10.1016/j.tox.2010.01.007. Epub 2010 Jan 15.

PMID:
20079798
48.

Anthracycline extravasation: a comprehensive review of experimental and clinical treatments.

Langer SW, Sehested M, Jensen PB.

Tumori. 2009 May-Jun;95(3):273-82. Review.

PMID:
19688963
49.

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.

Marquard L, Poulsen CB, Gjerdrum LM, de Nully Brown P, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E.

Histopathology. 2009 May;54(6):688-98. doi: 10.1111/j.1365-2559.2009.03290.x.

PMID:
19438744
50.

Characterization of DLK1+ cells emerging during skeletal muscle remodeling in response to myositis, myopathies, and acute injury.

Andersen DC, Petersson SJ, Jørgensen LH, Bollen P, Jensen PB, Teisner B, Schroeder HD, Jensen CH.

Stem Cells. 2009 Apr;27(4):898-908. doi: 10.1634/stemcells.2008-0826.

Supplemental Content

Loading ...
Support Center